

The role of microbes in large-scale vitamin and amino acid production.

Fatima Khan*

Department of Biotechnology, Massachusetts Institute of Technology (MIT), USA

*Correspondence to: Fatima Khan, Department of Biotechnology, Massachusetts Institute of Technology (MIT), USA, E-mail: fatimasalmanshah@gmail.com

Received: 09-May-2025, Manuscript No. AAMCR-25-171304; **Editor assigned:** 10-May-2025, PreQC No. AAMCR-25-171304 (PQ); **Reviewed:** 22-May-2025, QC No. AAMCR-25-171304; **Revised:** 24-May-2025, Manuscript No. AAMCR-25-171304 (R); **Published:** 30-May-2025, DOI: 10.35841/aamcr-9.2.265

Introduction

Microorganisms have long been harnessed for industrial biotechnology, offering sustainable and scalable solutions for producing essential nutrients. Among their most impactful applications is the large-scale biosynthesis of vitamins and amino acids—compounds critical for human health, animal nutrition, and pharmaceutical manufacturing. Microbial fermentation has revolutionized the production of these biomolecules, replacing traditional chemical synthesis with eco-friendly, cost-effective, and high-yield processes. This article explores the microbial mechanisms, industrial strategies, and future prospects of microbial production of vitamins and amino acids [1].

Microbial production of vitamins and amino acids offers significant sustainability advantages. It reduces reliance on petrochemical feedstocks, minimizes hazardous waste, and lowers energy consumption. Moreover, microbial processes can utilize agricultural by-products, contributing to circular bioeconomy models. Economically, the global market for amino acids and vitamins produced via fermentation is expanding, driven by demand in food, feed, and pharmaceutical sectors. China, the United States, and Europe are leading producers, with increasing investment in biotech infrastructure. Microbial fermentation involves cultivating specific strains of bacteria, fungi, or yeast under controlled conditions to produce target compounds. The process is optimized through metabolic engineering, strain selection, and bioprocess control. Vitamins such as B2 (riboflavin), B12 (cobalamin), and C (ascorbic acid), as well as amino acids like lysine, glutamate, and tryptophan, are now predominantly produced via microbial fermentation. This shift from

chemical synthesis to microbial production has reduced environmental impact, improved product purity, and enabled production from renewable feedstocks such as glucose, molasses, and agricultural waste [2].

Ashbya gossypii, a filamentous fungus, and *Bacillus subtilis* are widely used for riboflavin production. Genetic modifications in *B. subtilis* have enhanced flux through the riboflavin biosynthetic pathway, increasing yields significantly. Riboflavin is essential for cellular respiration and is used in food fortification and animal feed. Vitamin B12 is exclusively synthesized by microorganisms, particularly *Propionibacterium freudenreichii* and *Pseudomonas denitrificans*. Industrial production involves anaerobic fermentation, often requiring cobalt supplementation and complex nutrient media. B12 is vital for neurological function and red blood cell formation [3].

Synthetic biology allows the design of novel biosynthetic pathways and the integration of non-native genes, expanding the range of producible compounds. For example, synthetic operons have been constructed to improve vitamin B12 biosynthesis in *E. coli*, a non-native producer. Scaling microbial production from lab to industry involves optimizing fermentation conditions—pH, temperature, aeration, and nutrient supply. Fed-batch and continuous fermentation systems are employed to maintain high productivity. Downstream processing, including filtration, extraction, and purification, is tailored to the physicochemical properties of the target compound. Innovations in membrane technology and chromatography have improved efficiency and reduced costs. Although traditionally synthesized chemically, microbial processes using

Gluconobacter oxydans have been developed to convert D-sorbitol into 2-keto-L-gulonic acid, a precursor to ascorbic acid. This biotechnological route reduces toxic waste and energy consumption. *Corynebacterium glutamicum* is the workhorse for glutamate production, used extensively in the food industry as monosodium glutamate (MSG). Mutations affecting cell membrane permeability and TCA cycle regulation have been exploited to enhance glutamate excretion [4].

Lysine is an essential amino acid used in animal feed. *C. glutamicum* and *Escherichia coli* are engineered to overproduce lysine by deregulating feedback inhibition and enhancing precursor supply through the aspartate pathway. Tryptophan production involves *E. coli* strains engineered to overexpress genes in the shikimate pathway. The process is sensitive to oxygen levels and requires careful control of fermentation parameters. Tryptophan is used in pharmaceuticals and dietary supplements. These amino acids are produced using *E. coli* and *Brevibacterium flavum*. L-Phenylalanine is a precursor for the artificial sweetener aspartame, while L-Threonine is used in feed additives. Advances in metabolic engineering have enabled precise manipulation of microbial pathways to increase yields and reduce by-products. Techniques such as CRISPR-Cas9, genome shuffling, and adaptive laboratory evolution are used to optimize strains for industrial production [5].

Conclusion

Microbes play a pivotal role in the large-scale production of vitamins and amino acids, transforming industrial biotechnology and

contributing to global health and sustainability. Despite its success, microbial production faces challenges such as strain stability, contamination risks, and regulatory hurdles. Continuous research is needed to improve strain robustness and process scalability. Through metabolic engineering, synthetic biology, and process innovation, microbial fermentation continues to evolve, offering promising solutions for the future of nutrient manufacturing.

References

1. Rubenstein RC, Kreindler JL On preventing the extinction of the physician-scientist in pediatric pulmonology. *Front Pediatr*. 2014;2:4.
2. Esposito S, Principi N, ESCMID Vaccine Study Group (EVASG) Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. *Future Microbiol*. 2015;10(10):1599-607.
3. O'Brien K, Edwards A, Hood K, et al Prevalence of urinary tract infection in acutely unwell children in general practice: a prospective study with systematic urine sampling. *British J General Practice*. 2013;63(607):e156-64.
4. Donaghy JA, Danyluk MD, Ross T, et al. Big data impacting dynamic food safety risk management in the food chain. *Frontiers Microbiol*. 2021:952.
5. Mavani NR, Ali JM, Othman S, et al. Application of artificial intelligence in food industry-A guideline. *Food Engineering Reviews*. 2021:1-42.